全文获取类型
收费全文 | 420520篇 |
免费 | 28558篇 |
国内免费 | 5913篇 |
专业分类
耳鼻咽喉 | 5633篇 |
儿科学 | 8675篇 |
妇产科学 | 10642篇 |
基础医学 | 57195篇 |
口腔科学 | 12473篇 |
临床医学 | 35428篇 |
内科学 | 83872篇 |
皮肤病学 | 8985篇 |
神经病学 | 28874篇 |
特种医学 | 15469篇 |
外国民族医学 | 97篇 |
外科学 | 64673篇 |
综合类 | 18547篇 |
现状与发展 | 19篇 |
一般理论 | 69篇 |
预防医学 | 21230篇 |
眼科学 | 10393篇 |
药学 | 35680篇 |
50篇 | |
中国医学 | 4943篇 |
肿瘤学 | 32044篇 |
出版年
2022年 | 2715篇 |
2021年 | 4593篇 |
2020年 | 3190篇 |
2019年 | 4062篇 |
2018年 | 5894篇 |
2017年 | 4879篇 |
2016年 | 4772篇 |
2015年 | 5917篇 |
2014年 | 8041篇 |
2013年 | 9796篇 |
2012年 | 13245篇 |
2011年 | 13557篇 |
2010年 | 8686篇 |
2009年 | 7965篇 |
2008年 | 11783篇 |
2007年 | 12648篇 |
2006年 | 12392篇 |
2005年 | 11299篇 |
2004年 | 10558篇 |
2003年 | 10545篇 |
2002年 | 9925篇 |
2001年 | 29566篇 |
2000年 | 29668篇 |
1999年 | 24372篇 |
1998年 | 5590篇 |
1997年 | 4673篇 |
1996年 | 4097篇 |
1995年 | 3743篇 |
1994年 | 3339篇 |
1993年 | 2994篇 |
1992年 | 16194篇 |
1991年 | 14947篇 |
1990年 | 14257篇 |
1989年 | 14041篇 |
1988年 | 12642篇 |
1987年 | 12109篇 |
1986年 | 11151篇 |
1985年 | 10355篇 |
1984年 | 6923篇 |
1983年 | 5614篇 |
1982年 | 2725篇 |
1979年 | 5487篇 |
1978年 | 3351篇 |
1977年 | 2978篇 |
1975年 | 2642篇 |
1974年 | 3071篇 |
1973年 | 2871篇 |
1972年 | 2834篇 |
1971年 | 2775篇 |
1969年 | 2546篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的对比可弯曲胸腔镜和硬质胸腔镜在不明原因胸腔积液诊断中的准确性和安全性。方法采用前瞻性随机对照研究,连续筛选四川大学华西医院2012年3月至2014年3月期间不明原因胸腔积液住院患者,患者年龄18~75岁。经知情同意后,患者随机进入可弯曲胸腔镜组或硬质胸腔镜组进行检查。结果可弯曲胸腔镜组入组49例患者,硬质胸腔镜组入组48例患者。两组共有44例患者通过胸腔镜检查确诊为恶性疾病,48例确诊为良性疾病。两组诊断不明原因胸腔积液总体准确性分别为93.9%和95.8%,可弯曲胸腔镜组诊断肿瘤的敏感性为96.0%,硬质胸腔镜组诊断肿瘤的敏感性为95.2%,两组诊断肿瘤的特异性均为100.0%,两组之间差异无统计学意义。两种胸腔镜技术并发症多数轻微,患者均耐受良好。结论对于不明原因胸腔积液,可弯曲胸腔镜诊断的准确性与硬质胸腔镜相当。尽管可弯曲胸腔镜取材组织小,但是通过多点多次取材,所获得的组织标本能满足病理科医生进行包括免疫组织化学检测在内的疾病诊断。 相似文献
3.
4.
Yinlei
Wen Huaguang Zhang Hanguang Su He Ren 《Optimal control applications & methods.》2020,41(4):1233-1250
In this article, a model-free off-policy reinforcement learning algorithm is applied to address the optimal tracking problem based on multiplayer non-zero-sum games for discrete-time linear systems. In contrast to the traditional method and the policy iteration method for solving the optimal tracking problems, the proposed algorithm operates with the system data rather than the knowledge of the system dynamics. For performing the proposed algorithm, an auxiliary augmented system is constructed via assembling the original system and the reference trajectory while a discount factor is introduced into the performance indexes. It is analyzed that the solutions of the proposed algorithm converge to the Nash equilibrium and the result is not influenced by the probing noise. Two simulations are presented to verify the feasibility and effectiveness of the proposed algorithm. 相似文献
5.
6.
7.
【目的】 值此《中国科技期刊研究》创刊30周年之际,思考科研评价体系的改变给中文科技期刊带来的影响,为中文期刊探寻发展路径。【方法】 结合对中文科技期刊困境的研究,提出应对策略。【结果】 近期国家陆续出台的纠偏评价导向的政策文件,为中文科技期刊既带来了发展机遇,也提出了挑战。【结论】 在重构符合中文科技期刊发展特点的评价体系的基础上,中文科技期刊应明确目标定位,面向国家需求,提升知识服务能力,建立品牌特色。 相似文献
8.
9.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs. 相似文献
10.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献